Phaseline

Companies › Regenerative Ocular Immunobiologics

Regenerative Ocular Immunobiologics: clinical trials, targets and expected readouts

1 active drug program in 2 registered trials: 1 Phase 3, 1 Phase 1; Immunology, Ophthalmology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
d-MAPPS™ Ophthalmic Solution
unclear - preservative-free ophthalmic immunobiologic solution
–Phase 3oGVHD; oGHVDDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06852768d-MAPPS™ Ophthalmic SolutionPhase 1oGHVDOphthalmologyDec 2026
NCT07776210d-MAPPS™ Ophthalmic SolutionPhase 3oGVHDImmunologyMar 2027

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Doron Therapeutics UnicoCell Biomed medac ALK-Abelló Kolon TissueGene

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.